Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)
Avatar

Evolution of Transplant Approaches in MPN: Optional Conditioning Regimen, Source of Stem Cells, Optimal GVHD Prophylaxis, SOS Prevention, Optimal HCT Timing, Predictors of Outcomes, Pre- / Post- JAK2

By Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019) FEATURING David S. Snyder
By Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019) FEATURING David S. Snyder
227 views
November 18, 2019
0 Comments
Login to view comments. Click here to Login

Featured Video

13:04
Winship Cancer Institute - Emory University

Treatment-Related Quality of Life in MF

Feat. A. Hunter

Featured Video

06:51
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Prevalence and Prediction of Ruxolitinib Tr…

Feat. D. Tremblay

Related Content

AUTOPLAY
27:37
Indy Hematology Review

Review of Myeloproliferative Neoplasms

Feat. A. Tefferi
18:04
Ruben Mesa

Momelotinib for Myelofibrosis: Top 10 Things You Should Know Post-FD…

08:18
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Treatment Strategies for Hematocrit Control…

Feat. A. Zhou
05:20
Prithviraj Bose

When to Switch From Hydroxyurea to Ruxolitinib in PV

15:14
Icahn School of Medicine at Mount Sinai

Safety Profile of Ruxolitinib in Patients With MF

Feat. D. Tremblay
31:43
Indy Hematology Review

Myelofibrosis: Chronic and Blast Phase - 2023 Algorithms for Risk St…

Feat. A. Tefferi
21:52
Insights from 2023 ASH Annual Meeting

ASH 2023 Summary: "MF, ET, and PV - Highlights and Clinical Imp…

Feat. D. Tremblay
10:02
Insights from 2023 ASH Annual Meeting

ASH 2023 Summary: "The Best of MPNs - Highlights & Key Take…

Feat. R. Mesa
09:27
ASH 2022 Conference Coverage

MAJIC-PV Trial: Ruxolitinib vs. Best Available Therapy for PV Intole…

Feat. M. McMullin
12:18
Fred Hutchinson Cancer Center

Management of MPNs for the Community Oncologist

Feat. H. Deeg
12:07
Douglas Tremblay

Monitoring Patients With MF: When to Switch Treatment

16:25
Northwestern Medicine Oncology and Hematology

Diagnosis and Goals of Therapy in PV

Feat. B. Stein
09:46
Scripps MD Anderson Cancer Center

Ruxolitinib in Polycythemia Vera: Learnings From the RESPONSE Trial

Feat. D. Hermel
08:44
Krisstina Gowin

Management of Aquagenic Pruritis in Polycythemia Vera

11:39
Penn Medicine's 2024 Updates in Care of the Hematologic Malignancies Patient

2024 Updates in Myeloproliferative Neoplasms

Feat. E. Hexner
17:51
Penn Medicine Cellicon Valley '23: The Future of Cell and Gene Therapies

Chronic GVHD: A Case-Based Discussion

Feat. L. Perry
51:20
Jerry Spivak

Polycythemia Vera: Disease Overview, Treatment Landscape, and Curren…

53:01
PleXus Communications

Changing Pharmacological Paradigms for Higher-Risk Myelofibrosis

Feat. R. Rampal
15:31
Icahn School of Medicine at Mount Sinai

Myelofibrosis Treatment Options Beyond the JAK/STAT Pathway

Feat. M. Kremyanskaya
11:09
Jeanne Palmer

Management of Clinical Manifestations in Myelofibrosis